MedTrace Logo

Oral Immunotherapy for Peanut Allergy (PMIT)

NCT00597675 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if mucosal peanut immunotherapy will make subjects who have peanut allergy less allergic and induce changes in their immune system.

Conditions

  • Food Hypersensitivity

Interventions

BIOLOGICAL

Peanut OIT

Defatted peanut flour ingested daily as oral mucosal immunotherapy

BIOLOGICAL

Placebo

Oat flour matched by weight and consistency that is ingested daily as a placebo

Sponsors & Collaborators

  • University of Arkansas

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Arvil W Burks, MD · University of North Carolina, Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00597675 on ClinicalTrials.gov